Discovery of a potent and selective aurora kinase inhibitor.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2008-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmcl.2008.07.073PMID 18678489
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aurora Kinases as Anticancer Drug Targets

  2008cited by this paper
• Aurora kinase inhibitors: identification and preclinical validation of their biomarkers

  2008cited by this paper
• Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase

  2007cited by this paper
• Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors.

  2007cited by this paper
• AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis

  2007cited by this paper
• Aurora Kinases: New Targets for Cancer Therapy

  2006cited by this paper
• Aurora kinase inhibitors: a new class of targeted drugs in cancer.

  2006cited by this paper
• PHA-680632, a Novel Aurora Kinase Inhibitor with Potent Antitumoral Activity

  2006cited by this paper
• Validating Aurora B as an anti-cancer drug target

  2006cited by this paper
• Therapeutic potential of Aurora kinase inhibitors in cancer.

  2006cited by this paper
• Aurora-A — A guardian of poles

  2005cited by this paper
• Progress in the development of selective inhibitors of Aurora kinases.

  2005cited by this paper
• Aurora kinases: shining lights on the therapeutic horizon?

  2005cited by this paper
• VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

  2004cited by this paper
• Aurora-kinase inhibitors as anticancer agents

  2004cited by this paper
• The Aurora kinases: Role in cell transformation and tumorigenesis

  2003cited by this paper
• The cellular geography of Aurora kinases

  2003cited by this paper
• Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores

  2003cited by this paper
• A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers

  1998cited by this paper
• Histamine H2-receptor agonists. Synthesis, in vitro pharmacology, and qualitative structure-activity relationships of substituted 4- and 5-(2-aminoethyl)thiazoles.

  1992cited by this paper

• Thienopyrimidine: A promising scaffold in the development of kinase inhibitors with anticancer activities.

  2025cites this paper
• Screen of the ReFRAME Compound Library for Therapeutic Agents to Prevent Red Blood Cell Sickling Using an Improved High Throughput Sickling Assay

  2025cites this paper
• The two sides of chromosomal instability: drivers and brakes in cancer

  2024cites this paper
• Design, synthesis and anticancer evaluation of 4-Substituted 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidines as dual topoisomerase I and II inhibitors.

  2024cites this paper
• Synthesis, design, and antiproliferative evaluation of 6-(N-Substituted-methyl)pyrazolo[3,4-d]pyrimidines as the potent anti-leukemia agents.

  2024cites this paper
• Fused thiophene as a privileged scaffold: A review on anti-Alzheimer's disease potentials via targeting cholinesterases, monoamine oxidases, glycogen synthase kinase-3, and Aβ aggregation.

  2024cites this paper
• Synthesis of Thieno[3,2‐d]pyrimidine Derivatives through Sequential SNAr and Suzuki Reactions as Selective h‐NTPDase Inhibitors

  2023cites this paper
• Aurora B Inhibitors as Cancer Therapeutics

  2023cites this paper
• High-Throughput Assay to Screen Small Molecules for Their Ability to Prevent Sickling of Red Blood Cells

  2022cites this paper
• Design, Synthesis and Biological Evaluation of Substituted Amide Derivatives of Isoxazole-Thieno[2,3-D]Pyrimidines as Anticancer Agents

  2022cites this paper
• Centrosome Aberrations as Drivers of Chromosomal Instability in Breast Cancer.

  2021cites this paper
• Discovery of potential Aurora-A kinase inhibitors by 3D QSAR pharmacophore modeling, virtual screening, docking, and MD simulation studies

  2021influential citation
• Imidazopyridine, a promising scaffold with potential medicinal applications and structural activity relationship (SAR): recent advances

  2021cites this paper
• Second-Generation Antimitotics in Cancer Clinical Trials

  2021cites this paper
• Development of a Robust Scale-Up Synthetic Route for BPR1K871: A Clinical Candidate for the Treatment of Acute Myeloid Leukemia and Solid Tumors

  2021cites this paper
• Tandem synthesis and antibacterial screening of novel thieno[2,3-b]thiophene-linked bis(thiazole) hybrids

  2021cites this paper
• Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells

  2021cites this paper
• Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer

  2021cites this paper
• A New Quantitative Cell-Based Assay Reveals Unexpected Microtubule Stabilizing Activity of Certain Kinase Inhibitors, Clinically Approved or in the Process of Approval

  2020cites this paper
• Synthesis and Anticancer Activity of Functionalized Thieno[2,3-d]pyrimidine Compounds and Their Triazinyl and Tetrazinyl Derivatives

  2020cites this paper
• Therapeutic aspects of the Axl/Gas6 molecular system.

  2020cites this paper
• A look into the link between centrosome amplification and breast cancer.

  2020cites this paper
• Exploring new structural features of the 4-[(3-methyl-4-aryl-2,3-dihydro-1,3-thiazol-2-ylidene)amino]benzenesulphonamide scaffold for the inhibition of human carbonic anhydrases

  2019cites this paper
• AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications

  2019cites this paper
• Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.

  2019cites this paper
• Discovery of novel 2,4-disubstituted pyrimidines as Aurora kinase inhibitors.

  2019cites this paper
• Synthesis, crystal and antiproliferative activity of 2-[2-(2-fluorobenzylidene) hydrazinyl]-4-(1-methyl-1H-indol-3-yl)thieno[3,2-d]pyrimidine

  2019cites this paper
• Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states

  2018cites this paper
• Structure-based drug design: Synthesis and biological evaluation of quinazolin-4-amine derivatives as selective Aurora A kinase inhibitors.

  2018cites this paper
• Spindle Assembly Checkpoint as a Potential Target in Colorectal Cancer: Current Status and Future Perspectives

  2017cites this paper
• The Role of Human Papillomaviruses in the Aetiopathogenesis of Head and Neck Cancer in South Asia, and Approaches to Treatment

  2017cites this paper
• Significance of Thiazole-based Heterocycles for Bioactive Systems

  2017cites this paper
• A dynamic mechanism for allosteric activation of Aurora kinase A by activation loop phosphorylation

  2017cites this paper
• Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma

  2017cites this paper
• Design, synthesis and anti-cancer evaluation of a novel series of pyrazolo [1, 5-a] pyrimidine substituted diamide derivatives

  2017cites this paper
• 1 A dynamic mechanism for allosteric activation of Aurora kinase A by activation loop 1 phosphorylation 2 3

  2017cites this paper
• The Aurora kinase inhibitors in cancer research and therapy

  2016cites this paper
• Maintaining Genome Stability in Defiance of Mitotic DNA Damage

  2016cites this paper
• Targeting the interaction of Aurora kinases and SIRT1 mediated by Wnt signaling pathway in colorectal cancer: A critical review.

  2016cites this paper
• Design, synthesis, and evaluation of hinge-binder tethered 1,2,3-triazolylsalicylamide derivatives as Aurora kinase inhibitors.

  2016cites this paper
• Novel Solid‐phase and Solution‐phase Synthetic Methods for Trisubstituted Thieno[3,2‐d]pyrimidine Derivatives

  2016cites this paper
• Aurora‐A Kinase: A Potent Oncogene and Target for Cancer Therapy

  2016cites this paper
• Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation

  2016cites this paper
• Structural Biology Insight for the Design of Sub-type Selective Aurora Kinase Inhibitors.

  2015cites this paper
• Functions of Aurora kinase C in meiosis and cancer

  2015cites this paper
• State-of-the-art of small molecule inhibitors of the TAM family: the point of view of the chemist.

  2015cites this paper
• Identification of signalling cascades involved in red blood cell shrinkage and vesiculation

  2015cites this paper
• Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell lines.

  2015cites this paper
• Comparing sixteen scoring functions for predicting biological activities of ligands for protein targets.

  2015cites this paper
• Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors

  2014cites this paper
• A combined approach based on 3D pharmacophore and docking for identification of new aurora A kinase inhibitors

  2014cites this paper
• Click approach to the discovery of 1,2,3-triazolylsalicylamides as potent Aurora kinase inhibitors.

  2014cites this paper
• Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.

  2014cites this paper
• Neuroprotective effect compound and preparation method and use thereof

  2014cites this paper
• Discovery of 4-aminoquinazoline--urea derivatives as Aurora kinase inhibitors with antiproliferative activity.

  2014cites this paper
• Classification of Aurora B kinase inhibitors using computational models.

  2014cites this paper
• Aurora Kinases as Druggable Targets in Pediatric Leukemia: Heterogeneity in Target Modulation Activities and Cytotoxicity by Diverse Novel Therapeutic Agents

  2014cites this paper
• A tandem and tunable Pd catalyzed C–N coupling of heteroarenols with ureas via C–OH bond activation

  2014cites this paper
• Benzimidazole-biologically attractive scaffold for protein kinase inhibitors

  2014cites this paper
• Identification of new novel scaffold for Aurora A inhibition by pharmacophore modeling and virtual screening

  2014cites this paper
• The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing.

  2013cites this paper
• Synthesis of some novel thieno[3,2-d]pyrimidines as potential cytotoxic small molecules against breast cancer.

  2013cites this paper
• Classification of Aurora kinase inhibitors by self-organizing map (SOM) and support vector machine (SVM).

  2013cites this paper
• Design, synthesis, and in vitro antitumor evaluation of novel phenylaminopyrimidine derivatives.

  2013cites this paper
• Kinase inhibitors of marine origin.

  2013cites this paper
• Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine Aurora kinase inhibitor.

  2013cites this paper
• Kinase Inhibitors in Cancer

  2013cites this paper
• Computational methods for prediction of protein-ligand interactions

  2012cites this paper
• Design, synthesis & evaluation of human Aurora kinase and phosphodiesterase inhibitors for anti-trypanosomal drug discovery via target repurposing

  2012cites this paper
• ENMD-2076 for hematological malignancies

  2012cites this paper
• Significance estimation for sequence-based chemical similarity searching (PhAST) and application to AuroraA kinase inhibitors.

  2012cites this paper
• Aurora kinase inhibitors: Progress towards the clinic

  2012cites this paper
• Rationalizing Tight Ligand Binding through Cooperative Interaction Networks

  2011cites this paper
• Update on aurora kinase targeted therapeutics in oncology

  2011cites this paper
• Application of shape-based and pharmacophore-based in silico screens for identification of Type II protein kinase inhibitors

  2011cites this paper
• Prediction of biological activity of Aurora-A kinase inhibitors by multilinear regression analysis and support vector machine.

  2011cites this paper
• A Molecular Mechanics Approach to Modeling Protein-Ligand Interactions: Relative Binding Affinities in Congeneric Series

  2011cites this paper
• Classification of Aurora‐A Kinase Inhibitors Using Self‐Organizing Map (SOM) and Support Vector Machine (SVM)

  2011cites this paper
• 3D-QSAR and Molecular Docking Studies on Derivatives of MK-0457, GSK1070916 and SNS-314 as Inhibitors against Aurora B Kinase

  2010cites this paper
• Aurora A and B kinases--targets of novel anticancer drugs.

  2010cites this paper
• Aurora kinase inhibitors as anticancer molecules.

  2010cites this paper
• Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells.

  2010cites this paper
• Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the Imidazo-[1,2-a]-Pyrazine Core.

  2010cites this paper
• Identification, SAR Studies, and X‐ray Co‐crystallographic Analysis of a Novel Furanopyrimidine Aurora Kinase A Inhibitor

  2010cites this paper
• Kinase Inhibitors: Approved Drugs and Clinical Candidates

  2010cites this paper
• SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo

  2010cites this paper
• 3D-QSAR and Molecular Docking Studies on Derivatives of MK-0457, GSK1070916 and SNS-314 as Inhibitors against

  2010cites this paper
• A sensitive and selective liquid chromatography/tandem mass spectrometry method for determination of MLN8237 in human plasma.

  2010cites this paper
• AT-9283, a small-molecule multi-targeted kinase inhibitor for the potential treatment of cancer.

  2010cites this paper
• Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate.

  2010cites this paper
• Small molecule aurora kinases inhibitors.

  2009cites this paper
• 2-Aminobenzimidazoles as potent Aurora kinase inhibitors.

  2009cites this paper
• Advances in Aurora kinase inhibitor patents

  2009influential citation
• The multiple roles of computational chemistry in fragment-based drug design

  2009cites this paper
• The discovery of the potent aurora inhibitor MK-0457 (VX-680).

  2009cites this paper
• Clinical experience with aurora kinase inhibitors: a review.

  2009cites this paper
• Discovery and development of aurora kinase inhibitors as anticancer agents.

  2009cites this paper
• Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.

  2009cites this paper
• Aurora kinase inhibitors in preclinical and clinical testing

  2009cites this paper
• Advances in fragment-based drug discovery platforms

  2009cites this paper